In this video, health-care analyst David Williamson takes a closer look at Pfizer's first-quarter results and guidance reduction. Diving past the headlines, investors need to look to the future when valuing the potential of this Big Pharma.

Watch and get a succinct breakdown of the first quarter and find out what critical catalysts are coming for Pfizer investors in the near future.

Editor's note: Xeljanz has not been officially rejected in Europe, but it did recently receive a negative opinion from the European Medicines Agency.

David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.